Financial news in brief: Avecho CBD trial latest; Argent’s milestone delivery; Neurotech reassures ASX by Steve Jones April 29, 2026April 29, 2026 Avecho Biotechnology dosed 244 patients in its phase III insomnia trial, 16% above target, in a […]
Autism data hits ‘registration benchmark’ as Neurotech prepares for Phase III clinical trial by Adam Sheldon March 25, 2026March 26, 2026
News in brief: Vitura signs MedReleaf deal; Neurotech initiates first site for Phase 3 autism trial by Adam Sheldon March 17, 2026March 17, 2026
News in brief: Epsilon launches biotech arm; LGP sells WA facility for $7.8m; Neurotech partners with University of Sydney on Rett program by Adam Sheldon February 18, 2026February 19, 2026
Financial news in brief: Avecho; InhaleRx; Neurotech; Peak; Zelira; Argent by Adam Sheldon February 2, 2026February 5, 2026
News in brief: Wentzel wins US award; Neurotech NTI164 study published by Adam Sheldon January 19, 2026January 19, 2026
News in brief: Provocatus names Luke Gartner as managing director; Nurotech’s FDA boost by Adam Sheldon and Martin Lane October 8, 2025February 21, 2026
Neurotech to release paediatric cannabis drug through Authorised Prescribers by Adam Sheldon September 24, 2025February 21, 2026
Dr Bonni Goldstein joins Neurotech push to register cannabis drug for paediatric patients by Steve Jones June 16, 2025June 16, 2025
PK study shows further promise for Neurotech paediatric CBDA drug by Steve Jones June 3, 2025June 3, 2025
